
    
      This is a Phase 1/2a, randomized, double-blind, placebo-controlled, dose-escalation,
      multicenter study to evaluate the safety and tolerability of multiple doses of MEDI-534 at
      10^5 or 10^6 median tissue culture infectious dose (TCID50) in RSV and PIV3 seronegative
      children 6 to <24 months of age and at dosages of 10^4, 10^5 or 10^6 TCID50 in unscreened
      infants 2 months of age.
    
  